What WHO Announced
On 24 August 2020, WHO, Gavi, the Vaccine Alliance, and CEPI announced that 172 economies were engaged in discussions to join COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. COVAX was created to pool procurement and share development risk so that participating countries — high-, middle- and low-income alike — could obtain doses of safe and effective COVID-19 vaccines once licensed and approved.
Key points from the announcement:
- Nine CEPI-supported candidate vaccines were in the portfolio (including Moderna and AstraZeneca/Oxford in Phase III; Inovio, Novavax, CureVac, Clover Biopharmaceuticals and University of Queensland/CSL in earlier phases), with nine more under evaluation and additional manufacturer talks ongoing.
- 80 potentially self-financing economies had submitted non-binding expressions of interest, alongside 92 low- and middle-income economies eligible for support through the COVAX Advance Market Commitment (AMC).
- Together these 172 economies represented more than 70% of the world's population.
- Stated goal: deliver 2 billion approved doses by the end of 2021, allocated proportional to population, prioritising health workers first, then older adults and people with pre-existing conditions, plus a humanitarian buffer stockpile.
- Funding gaps were flagged: an extra US$1 billion for R&D and a US$2 billion AMC seed target (then at ~US$600 million).
This was a policy and financing announcement, not a travel restriction, border measure, or entry requirement. It contained no clinical guidance for individual travellers.
Why It Mattered for Travellers
COVAX influenced where and when vaccine supply became available globally — which in turn shaped national vaccination campaigns and, later, proof-of-vaccination requirements at borders. For travellers, the practical takeaway in 2020 was that vaccine availability would vary substantially by destination.
Pharmacist's note: This item is from August 2020 and is now of historical interest only. COVID-19 vaccine products, approvals, schedules and documentation rules have changed repeatedly since. Treat the dose figures, trial phases and country lists above as a snapshot, not current guidance. If you are planning international travel, verify requirements through the destination's official immigration or health ministry site and your national travel-health service, and confirm which vaccine products are recognised there — recognition lists have historically differed between WHO Emergency Use Listing and individual national regulators. Any decision about personal immunisation, timing, or boosters should be made with your own prescriber, travel clinic, or pharmacist who can review your history. This summary is public information only and is not individual medical advice.